Atelvia (risedronate sodium) delayed-release tablets contain a pH-sensitive enteric coating and a chelating agent (EDTA).
Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each Atelvia tablet for oral administration contains the equivalent of 35 mg of anhydrous risedronate sodium in the form of the hemi-pentahydrate with small amounts of monohydrate. The empirical formula for risedronate sodium hemi-pentahydrate is C7H10NO7P2Na•2.5H2O. The chemical name of risedronate sodium is [1-hydroxy-2-(3pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt.
Risedronate sodium is a fine, white to off-white, odorless, crystalline powder. It is soluble in water and in aqueous solutions, and essentially insoluble in common organic solvents.
Edetate disodium, ferric oxide yellow, magnesium stearate, methacrylic acid copolymer, polysorbate 80, silicified microcrystalline cellulose (ProSolv SMCC90), simethicone, sodium starch glycolate, stearic acid, talc, and triethyl citrate.
- Atelvia Information for Consumers
- Atelvia Information for Healthcare Professionals (includes dosage details)
- Side Effects of Atelvia (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 14 May 2010 • 2 answers
Posted 1 Feb 2013 • 1 answer
Posted 12 Dec 2013 • 1 answer
Posted 15 Jul 2015 • 1 answer
Posted 22 Jun 2017 • 1 answer